Dry eye disease affects millions, causing discomfort and vision problems due to increased friction between the cornea and conjunctiva. Traditional treatments offer limited relief, failing to address the underlying issue of insufficient lubrication and inflammation on the ocular surface. This unmet need leaves patients seeking more effective solutions to alleviate symptoms and prevent further damage.

Lubris BioPharma develops recombinant human lubricin to address the root cause of dry eye disease by reducing friction and wear on the ocular surface. Lubricin, a naturally occurring glycoprotein, protects tissues from friction-related damage. By supplementing the diminished levels of lubricin in dry eye patients, the therapy aims to restore homeostasis to the tear film, prevent inflammation, and improve patient comfort. The recombinant lubricin acts as a biological lubricant, mimicking the function of Teflon to coat and protect the eye's surface. This approach offers a potential improvement over existing treatments by targeting the underlying biomechanical issues contributing to dry eye symptoms.

Recombinant human lubricin formulation designed for topical administration.

Aims to reduce friction between the cornea and conjunctiva.

Designed to prevent inflammation and shear stress on the ocular surface.

May improve biocompatibility and extend wear time of contact lenses.

Addresses lubricin deficiency, a key factor in moderate to severe dry eye.

The primary target audience includes individuals suffering from dry eye disease, particularly those with moderate to severe symptoms seeking more effective and long-lasting relief.